人血制品和免疫制品

🧬 Human Blood Products & Immune Preparations

🌐 HS Code Reference & Customs Clearance Guide | 2026 Latest Tariff Analysis | Professional Clearance Strategy
📌 I. Product Definition & Classification: Do You Really Understand "Human Blood Products"?

Human blood products and immune preparations fall under the broad category of human blood, antisera, and immunological products. These are high-value, highly regulated biological substances derived from human plasma or blood components. They include:

• Blood Components: Red blood cells, white blood cells, platelets, plasma.
• Immunological Products: Antisera, vaccines (where classified under Chapter 30), and therapeutic immunoglobulins.
• Derived Preparations: Albumin, clotting factors, and other protein concentrates.

⚠️ Key Distinction:
- If the product is a raw blood component or immunological preparation not specifically listed elsewhere (like vaccines in 3002.19 or specific monoclonal antibodies), it falls under 3002.12 or 3002.13.
- If it is an organ/tissue extract used for therapeutic purposes, it may fall under 3001.20.
- If it is a finished medicament containing antigens/antibodies, packaged for retail sale, it may fall under 3004.90.

📦 II. HS Code Classification Details (2026 Latest Tariff Authoritative Comparison)

🔍 Key Reminder:
- 3002.12/3002.13: For blood fractions and immunological preparations that are not finished medicaments.
- 3001.20: For organ extracts (e.g., hormone extracts, though less common for "blood products" per se, it covers the "extract" aspect).
- 3004.90.10.00: For finished pharmaceuticals that contain immune components (antigens/antibodies) but are not classified under 3002 or 3005.
- No Monoclonal Antibody Conflict: The summary for 3002.13.00.90 explicitly notes it covers immune preparations excluding specific conflicts like monoclonal antibodies (which might fall elsewhere) or计量剂量包装 (metered doses).

💰 III. 2026 Latest Tariff Rate Details (Including Surcharges, Policy Add-ons)

✅ Applicable Country: United States (US)
✅ Country of Origin: China (CN)
✅ Effective Date: From November 10, 2025 (including subsequent imports)

🎯 1. 3002.12.00.90 —— Other Human Blood Components / Antisera

📌 Explanation:
- Base Rate: 0% for most medical/biological imports under Chapter 30.
- Section 122 Tariff (+10%): A specific surcharge applied to certain Chinese-origin biological/medical products under Section 122 provisions.
- Total: 10%. This is significantly lower than the 25%+ Section 301 tariffs on many electronics.

🎯 2. 3002.13.00.90 —— Immune Preparations

📌 Note:
- Identical tariff structure to 3002.12.00.90.
- Applies to human immunoglobulins and immune sera.
- No conflict with monoclonal antibodies (which might have different classifications).

🎯 3. 3001.20.00.00 —— Glands and Other Organs Extracts

📌 Explanation:
- Applies when the product is framed as an extract of glands or organs (e.g., specific protein isolates from blood/organ tissue) rather than a "blood component" or "immune preparation."
- Core Requirement: Must fit the definition of "extracts of glands or other organs."

🎯 4. 3004.90.10.00 —— Finished Medicaments with Immune Components

📌 Key Distinction:
- This code is for finished medicaments (packaged for retail, with dosage).
- Core Requirement: Must contain antigens, antibodies, or other immunological products.
- Exclusion: If it falls under 3002 (blood fractions) or 3005/3006, it does not go here.
- Example: A boxed vial of anti-venom or a specific immunotherapy drug.

🛠️ IV. Customs Clearance Practical Advice (Real-World Pitfall Guide)

✅ 1. Preparation Checklist (All Must-Haves)

✅ 2. Declaration Tips (Key Mantra)

🔥 “Biologicals Are Special, FDA First, HS Precise, Section 122 Pays!”

📌 Critical Point:
- FDA Prior Notice is non-negotiable for human blood products.
- Section 122 (10%) applies to all these codes for Chinese origin. Do not assume they are duty-free because the base rate is 0%.

✅ 3. Special Cases Handling

🌍 V. Global Market Comparison (2026 Latest)

📌 Conclusion:
- USA applies a 10% Section 122 tariff on Chinese-origin human blood/immune products.
- FDA compliance is the biggest hurdle, not just the tariff.
- Cold chain logistics are critical to avoid spoilage and rejection.

📌 VI. Common Mistakes & Pitfall Guide (Blood-Letting Lessons)

❌ Mistake 1: Ignoring FDA Prior Notice
👉 Consequence: Cargo rejected at port, destroyed or re-exported.
❌ Mistake 2: Misclassifying Finished Medicaments as Blood Fractions
👉 Consequence: Wrong HS Code (3002 vs 3004), potential penalties for misdeclaration.
❌ Mistake 3: Not declaring Section 122 Tariff
👉 Consequence: Underpayment of 10% tariff → Back taxes + Penalties.
❌ Mistake 4: Poor Cold Chain Documentation
👉 Consequence: FDA questions product stability → Seizure.

✅ Correct Approach:

“Human Immunoglobulin, Lyophilized, for Intravenous Use, 5g Vial, Store at 2-8°C, FDA Prior Notice #XXXXXXXX, HS Code 3002.13.00.90”

🎯 VII. Conclusion: Precise Classification, Safe Clearance!

🎯 Remember the Mantra:

🔹 “Biologicals Are High-Risk, FDA First, HS Precise, 10% Surcharge Paid!”
🔹 “Cold Chain Is King, Documentation Is Queen, One Mistake, Cargo Seen!”

📌 Pro Tip:
- Always apply for FDA Prior Notice at least 5 days before shipment.
- Verify HS Code with a customs broker specializing in biological products.
- Budget for the 10% Section 122 tariff in your cost model.

📣 Immediate Action:

📞 Contact FDA Compliance Expert + Prepare Cold Chain Logs + Apply for HS Code Advance Ruling
🚀 Ensure your human blood products clear customs safely, comply with FDA, and avoid costly delays!

✨ Professional Clearance Starts with Precision!
💼 Every biological product deserves the highest compliance standard!